Diflucan 150 mg (Fluconazole) and Macitentan: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Combined CYP3A4 and CYP2C9 inhibition may increase macitentan exposure.
Clinical significance and safety
Diflucan 150 mg (Fluconazole) and Macitentan: Fluconazole is a moderate dual inhibitor. European information recommends caution and notes uncertainty in modelling-based exposure predictions; the US label recommends avoiding moderate dual inhibition. A specialist should review the full medicine list. Do not change treatment yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.